Ethyl Dimethyl Ammonio Propane Sulfonate

Ethyl Dimethyl Ammonio Propane Sulfonate

SCHEMBL366902

CC[N+](C)(C)CCCS(=O)(=O)O

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BBOX1 O75936 4/20 0.63
DNM1 Q05193 3/20 0.44
HTT P42858 2/20 0.44
KMT2A Q03164 1/20 0.44
HSP90AA1 P07900 1/20 0.43
RAD52 P43351 1/20 0.43
APP P05067 1/20 0.41
ENPP2 Q13822 3/20 0.33
PTGS1 P23219 1/20 0.33
PDE4A P27815 1/20 0.33
LMNA P02545 1/20 0.33
SLC6A6 P31641 1/20 0.33
CYP2C19 P33261 1/20 0.33
BLM P54132 1/20 0.33
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Dimethyl Ammonio Propane Sulfonate SCHEMBL28051649 0.98 BBOX1 (0.61) BBOX1DNM1HTTKMT2AHSP90AA1
SCHEMBL17912434 0.93 BBOX1 (0.55) BBOX1DNM1HTTKMT2AHSP90AA1
SCHEMBL918271 0.88 BBOX1 (0.46) BBOX1DNM1HTTAPPPTGS1
Sulfuric Acid SCHEMBL29054639 0.88 BBOX1 (0.60) BBOX1DNM1HTTKMT2AHSP90AA1
SCHEMBL1864397 0.84 DNM1 (0.48) BBOX1DNM1HTTKMT2AAPP
SCHEMBL15382997 0.84 DNM1 (0.50) BBOX1DNM1HTTKMT2AHSP90AA1
Water SCHEMBL28532746 0.84 BBOX1 (0.48) BBOX1DNM1HTTKMT2AHSP90AA1
SCHEMBL22006989 0.84 BBOX1 (0.43) BBOX1DNM1HTTAPPPTGS1
Water SCHEMBL1271206 0.83 DNM1 (0.46) BBOX1DNM1HTTKMT2AAPP
Mecetronium SCHEMBL330982 0.82 DNM1 (0.63) BBOX1DNM1HTTKMT2AHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388896-A1 COMPOSITION AND METHODS FOR TRANSGENE INSERTION CELYNTRA THERAPEUTICS SA (BE) 2025-12-25 US claimed
EP-4486881-A1 COMPOSITION AND METHODS FOR TRANSGENE INSERTION Celyntra Therapeutics SA (BE) 2025-01-08 EP claimed
US-11999817-B1 Bismaleimide-thiol-epoxy polymer compositions, and methods of making and using the same HRL LABORATORIES, LLC (US) 2024-06-04 US claimed
WO-2023167882-A1 COMPOSITION AND METHODS FOR TRANSGENE INSERTION ARTISAN DEVELOPMENT LABS, INC. (US) 2023-09-07 WO claimed
WO-2019078655-A1 COMPOSITION FOR INFILTRATING BIOMOLECULE INTO TISSUE INCLUDING SULFOBETAINE-BASED ZWITTERIONIC SURFACTANT, AND USE THEREOF 재단법인대구경북과학기술원 2019-04-25 WO claimed
US-20180009840-A1 ENHANCED FUNCTIONALITY AND DELIVERY OF A PROTEIN FROM A POROUS SUBSTRATE BIO-RAD LABORATORIES, INC 2018-01-11 US claimed
EP-3024843-A1 ENHANCED FUNCTIONALITY AND DELIVERY OF A PROTEIN FROM A POROUS SUBSTRATE Bio-Rad Laboratories, Inc. (US) 2016-06-01 EP claimed
US-20150291874-A1 METHODS FOR MAKING AND USING NOVEL FOAMER COMPOSITIONS WEATHERFORD TECHNOLOGY HOLDINGS, LLC 2015-10-15 US claimed
US-9018145-B2 Foamer composition and methods for making and using same Lubrizol Oilfield Solutions, Inc. (US) 2015-04-28 US claimed
WO-2015013542-A1 ENHANCED FUNCTIONALITY AND DELIVERY OF A PROTEIN FROM A POROUS SUBSTRATE BIO-RAD LABORATORIES, INC. (US) 2015-01-29 WO claimed
US-7906109-B2 Pharmaceutical composition comprising an active principal and sulphobetaine LEK PHARMACEUTICALS D.D. (SL) 2011-03-15 US claimed
EP-1729794-B1 A PHARMACEUTICAL COMPOSITION COMPRISING A NON-DETERGENT SULPHOBETAINE LEK PHARMACEUTICALS (SI) 2008-07-09 EP claimed
US-20070184019-A1 Pharmaceutical composition comprising an active principal and sulphobetaine LEK PHARMACEUTICALS D.D. (SI) 2007-08-09 US claimed
EP-1729794-A1 A PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE PRINCIPLE AND SULPHOBETAINE LEK Pharmaceuticals D.D. (SI) 2006-12-13 EP claimed
US-20050250666-A1 Foamer/sulfur scavenger composition and methods for making and using same WEATHERFORD/LAMB, INC. 2005-11-10 US claimed
WO-2005060989-A1 A PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE PRINCIPLE AND SULPHOBETAINE LEK PHARMACEUTICALS D.D. (CH) 2005-07-07 WO claimed
US-20050137114-A1 environmentally friendly, biodegradable, nondepositing and high temperatures resistant aqueous foaming agents comprising a mixture of anionic, cationic and zwitterionic surfactants, used as drilling fluids WEATHERFORD/LAMB, INC. 2005-06-23 US claimed
WO-2005007895-A1 METHODS AND KITS FOR OBTAINING NUCLEIC ACID FROM BIOLOGICAL SAMPLES APPLERA CORPORATION (US) 2005-01-27 WO claimed
US-20050009036-A1 Methods and kits for obtaining nucleic acid from biological samples APPLERA CORPORATION (US) 2005-01-13 US claimed
US-6471841-B1 INCREASING ELECTROOSMOTIC FLOW; REDUCING ELECTROPHORETIC MOBILITY; EFFECTIVE CONCENTRATION OF 3-(N-ETHYL-N,N-DIMETHYL-AMMONIUM)PROPANESULFONATE; MICROFLUIDICS CALIPER TECHNOLOGIES CORP. 2002-10-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388896-A1 COMPOSITION AND METHODS FOR TRANSGENE INSERTION GDA, XPA, ERCC2 BBOX1 3065/4885DNM1 2445/4885HTT 190/4885
US-20070184019-A1 Pharmaceutical composition comprising an active principal and sulphobetaine SCN2B, SCN1B, SPTSSB BBOX1 1678/4885DNM1 1969/4885HTT 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.